Related Experiment Video

Updated: Nov 10, 2025

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
09:33

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

2.5K

Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India

Aakash Desai1,2, Bhawna Sirohi3, Aju Mathew4

  • 1Division of Medical Oncology, Department of Medicine, Mayoclinic, Rochester, MN, USA.

Cancer Investigation
|April 5, 2021
PubMed

Insights

Cancer clinical trials are crucial in low- and middle-income countries (LMICs) where the majority of cancer deaths occur. This commentary highlights the access challenges and proposes solutions, using India as a case study.

Area of Science:

  • Oncology
  • Global Health
  • Health Economics

Background:

  • Low- and middle-income countries (LMICs) bear a disproportionately high burden of global cancer deaths and disability.
  • Despite this burden, LMICs receive only 5% of global cancer research resources, leading to a significant mortality-to-income disparity.
  • There is a critical need to increase the number and accessibility of cancer clinical trials in LMICs.

Purpose of the Study:

  • To discuss the challenges and importance of conducting cancer clinical trials in LMICs.
  • To examine the problem of access to clinical trials in LMICs.
  • To use India as a specific case study to illustrate these issues.

Main Methods:

  • This is a commentary, not a primary research study.
  • The authors discuss existing data on global cancer burden and resource allocation.
  • India is presented as a case study to analyze access to clinical trials.

Main Results:

  • LMICs account for the majority of the projected 20 million cancer cases by 2030 and a higher proportion of cancer deaths and disability-adjusted life-years lost.
  • A significant disparity exists in cancer resource allocation, with LMICs receiving only 5% of global funding.
  • Barriers to accessing clinical trials in LMICs are identified and discussed.

Conclusions:

  • Conducting cancer clinical trials in LMICs is essential to address the global cancer burden effectively.
  • Improving access to clinical trials in LMICs is critical to reduce cancer mortality and improve patient outcomes.
  • Addressing resource disparities and specific challenges in countries like India is paramount for global cancer equity.
Keywords:
Clinical TrialsLMICsaccessdisparity

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.8K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

16.9K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
54
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
67
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
224
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.4K